The PCAST report's fourth recommendation is the creation of a new pathway that manufacturers could choose to use for initial approval of drugs shown to be safe and effective in a specific subgroup of patients.
Waxman discusses a recommendation for a new drug approval pathway for specific patient subgroups.
Share
More from Henry Waxman
We need to find answers to these questions, and I hope the committee will continue its investigation even after the time you and I, Mr. Chairman, will be gone.
We need to make sure that companies and regulators can keep pace with innovation.
the Federal Government would maintain its commitment to sharing the costs of providing basic healthcare and long-term coverage to vulnerable Americans.
Other voices in this conversation
